116 related articles for article (PubMed ID: 37608657)
1. Effect of Calcitriol in Inhibiting the Cancer Cell Growth and Promoting Apoptosis in ErbB2-positive Breast Cancer Cells.
Selvaraj NB; Swaroop AK; Mariappan E; Natarajan J; Thangavelu P; Selvaraj J
Anticancer Agents Med Chem; 2023; 23(18):2056-2071. PubMed ID: 37608657
[TBL] [Abstract][Full Text] [Related]
2. The addition of calcitriol or its synthetic analog EB1089 to lapatinib and neratinib treatment inhibits cell growth and promotes apoptosis in breast cancer cells.
Segovia-Mendoza M; Díaz L; Prado-Garcia H; Reginato MJ; Larrea F; García-Becerra R
Am J Cancer Res; 2017; 7(7):1486-1500. PubMed ID: 28744399
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D analog calcitriol for breast cancer therapy; an integrated drug discovery approach.
B S N; P K KN; Akey KS; Sankaran S; Raman RK; Natarajan J; Selvaraj J
J Biomol Struct Dyn; 2023 Dec; 41(20):11017-11043. PubMed ID: 37054526
[TBL] [Abstract][Full Text] [Related]
4. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
Cocco E; Javier Carmona F; Razavi P; Won HH; Cai Y; Rossi V; Chan C; Cownie J; Soong J; Toska E; Shifman SG; Sarotto I; Savas P; Wick MJ; Papadopoulos KP; Moriarty A; Cutler RE; Avogadri-Connors F; Lalani AS; Bryce RP; Chandarlapaty S; Hyman DM; Solit DB; Boni V; Loi S; Baselga J; Berger MF; Montemurro F; Scaltriti M
Sci Signal; 2018 Oct; 11(551):. PubMed ID: 30301790
[TBL] [Abstract][Full Text] [Related]
5. Endocytic degradation of ErbB2 mediates the effectiveness of neratinib in the suppression of ErbB2-positive ovarian cancer.
Wang S; Zhang J; Wang T; Ren F; Liu X; Lu Y; Xu L; Zhang Y; Wang D; Xu L; Wu Y; Liu F; Li Q; Zaky MY; Liu S; Dong W; Liu F; Zou K; Zhang Y
Int J Biochem Cell Biol; 2019 Dec; 117():105640. PubMed ID: 31689531
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2
Nagpal A; Redvers RP; Ling X; Ayton S; Fuentes M; Tavancheh E; Diala I; Lalani A; Loi S; David S; Anderson RL; Smith Y; Merino D; Denoyer D; Pouliot N
Breast Cancer Res; 2019 Aug; 21(1):94. PubMed ID: 31409375
[TBL] [Abstract][Full Text] [Related]
7. Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells.
Zhang Y; Zhang J; Liu C; Du S; Feng L; Luan X; Zhang Y; Shi Y; Wang T; Wu Y; Cheng W; Meng S; Li M; Liu H
Cancer Lett; 2016 Nov; 382(2):176-185. PubMed ID: 27597738
[TBL] [Abstract][Full Text] [Related]
8. Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.
Awada A; Colomer R; Inoue K; Bondarenko I; Badwe RA; Demetriou G; Lee SC; Mehta AO; Kim SB; Bachelot T; Goswami C; Deo S; Bose R; Wong A; Xu F; Yao B; Bryce R; Carey LA
JAMA Oncol; 2016 Dec; 2(12):1557-1564. PubMed ID: 27078022
[TBL] [Abstract][Full Text] [Related]
9. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
10. Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells.
Segovia-Mendoza M; Díaz L; González-González ME; Martínez-Reza I; García-Quiroz J; Prado-Garcia H; Ibarra-Sánchez MJ; Esparza-López J; Larrea F; García-Becerra R
J Steroid Biochem Mol Biol; 2015 Apr; 148():122-31. PubMed ID: 25510900
[TBL] [Abstract][Full Text] [Related]
11. Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor‑positive, human epidermal growth factor receptor 2‑positive breast cancer cells.
Lim ST; Jeon YW; Gwak H; Kim SY; Suh YJ
Mol Med Rep; 2018 Apr; 17(4):5581-5588. PubMed ID: 29436642
[TBL] [Abstract][Full Text] [Related]
12. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
Ribas R; Pancholi S; Rani A; Schuster E; Guest SK; Nikitorowicz-Buniak J; Simigdala N; Thornhill A; Avogadri-Connors F; Cutler RE; Lalani AS; Dowsett M; Johnston SR; Martin LA
Breast Cancer Res; 2018 Jun; 20(1):44. PubMed ID: 29880014
[TBL] [Abstract][Full Text] [Related]
13. Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer.
Oliveira M; Garrigós L; Assaf JD; Escrivá-de-Romaní S; Saura C
Expert Rev Anticancer Ther; 2020 Sep; 20(9):731-741. PubMed ID: 32862744
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
Brockhoff G; Heiss P; Schlegel J; Hofstaedter F; Knuechel R
Cytometry; 2001 Aug; 44(4):338-48. PubMed ID: 11500850
[TBL] [Abstract][Full Text] [Related]
16. Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo.
Schwab CL; English DP; Roque DM; Bellone S; Lopez S; Cocco E; Nicoletti R; Rutherford TJ; Schwartz PE; Santin AD
Gynecol Oncol; 2014 Oct; 135(1):142-8. PubMed ID: 25124161
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of drug response and gene profiling of HER2-targeted tyrosine kinase inhibitors.
Conlon NT; Kooijman JJ; van Gerwen SJC; Mulder WR; Zaman GJR; Diala I; Eli LD; Lalani AS; Crown J; Collins DM
Br J Cancer; 2021 Mar; 124(7):1249-1259. PubMed ID: 33473169
[TBL] [Abstract][Full Text] [Related]
18. HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
Canonici A; Ivers L; Conlon NT; Pedersen K; Gaynor N; Browne BC; O'Brien NA; Gullo G; Collins DM; O'Donovan N; Crown J
Invest New Drugs; 2019 Jun; 37(3):441-451. PubMed ID: 30062574
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.
Awada A; Dirix L; Manso Sanchez L; Xu B; Luu T; Diéras V; Hershman DL; Agrapart V; Ananthakrishnan R; Staroslawska E
Ann Oncol; 2013 Jan; 24(1):109-16. PubMed ID: 22967996
[TBL] [Abstract][Full Text] [Related]
20. A genome-wide RNAi screen identifies novel targets of neratinib sensitivity leading to neratinib and paclitaxel combination drug treatments.
Seyhan AA; Varadarajan U; Choe S; Liu Y; McGraw J; Woods M; Murray S; Eckert A; Liu W; Ryan TE
Mol Biosyst; 2011 Jun; 7(6):1974-89. PubMed ID: 21487605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
